« Return to News | Technology Solutions

Phase Forward Revenues Up 23%

Wednesday, October 29, 2008 09:22 AM

Waltham, Mass.-based eClinical technology company Phase Forward reported a 23% jump in third quarter revenues to $43 million from $34.9 million in the third quarter of 2007.

Non-GAAP net income for the period slid to $5.4 million compared with $6.9 million in the third quarter of 2007. The decline was due primarily to an increase in the company’s tax rate from 10.3% in the third quarter of 2007 to 36.2%, according to Phase Forward president and CEO Bob Weiler.

Weiler mentioned a number of Q3 highlights for the company, including a multi-year extension agreement with Eli Lilly and the recent acquisition of Clarix, a privately held provider of Web-integrated interactive response technology (IRT) based in Radnor, Pa.

“We continue to be optimistic about Phase Forward’s long-term opportunity, particularly considering the fact that we have recently expanded our market opportunity and value proposition with the acquisition of Clarix and its next generation interactive response technologies,” Weiler said in a company release. “The company’s broad range of offerings combined with our strong, debt-free balance sheet makes Phase Forward a financially secure business partner.”

Phase Forward's shares closed down 1.8% at $13.08 on Tuesday.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.